Education
About Us
Working with TipRanks
Follow Us
Zevra Therapeutics (ZVRA)
NASDAQ:ZVRA
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.18Last Year’s EPS
-0.4Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 11, 2025
|% Change Since: -12.76%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements such as the successful launch and FDA approval of MIPLYFFA, along with record revenue and expansion plans. However, there were challenges with the slower than expected OLPRUVA launch and increased net loss. Overall, the positives outweigh the negatives due to the strong start of MIPLYFFA and financial stability.Company Guidance
During the conference call, Zevra Therapeutics provided a detailed update on their strategic priorities and financial performance for the fourth quarter and full fiscal year 2024. Key metrics included the successful launch of MIPLYFFA, with 109 patient enrollment forms received in Q4, reflecting significant demand within the Niemann-Pick Disease Type C (NPC) community. Zevra reported net revenue of $12 million for Q4, with $10.1 million attributed to MIPLYFFA. The company aims to expand MIPLYFFA's availability outside the U.S., targeting a marketing authorization application in Europe by the second half of 2025, where 1,100 people are estimated to live with NPC. Zevra also highlighted their strategic pillars: commercial excellence, pipeline and innovation, talent and culture, and corporate foundation. They are leveraging infrastructure for both NPC and urea cycle disorders (UCDs), noting four OLPRUVA enrollments in Q4. Additionally, Zevra enrolled eight patients in their Phase 3 DiSCOVER trial for vascular Ehlers-Danlos Syndrome, bringing the total to 27. Financially, Zevra refinanced debt, completed a secondary offering, and plans to monetize a priority review voucher for $150 million, aiming to extend their cash runway into 2029.Successful Launch of MIPLYFFA
The launch of MIPLYFFA exceeded expectations with 109 patient enrollment forms received in the fourth quarter, marking a strong demand in the NPC community.
FDA Approval of MIPLYFFA
MIPLYFFA was approved by the FDA, becoming the first product in the U.S. for the treatment of Niemann-Pick Disease Type C (NPC).
Record Revenue
Zevra reported a record quarterly product revenue of $12 million in Q4 2024, with $10.1 million from MIPLYFFA.
Expansion Plans for MIPLYFFA
Plans to expand MIPLYFFA availability outside the U.S., with a focus on submitting a marketing authorization application in Europe during the second half of 2025.
Financial Stability
Zevra entered into an agreement to monetize its priority review voucher for $150 million, providing non-dilutive capital to support future growth.
---
ZVRA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ZVRA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 11, 2025 | $8.07 | $7.92 | -1.86% |
| Nov 12, 2024 | $8.57 | $8.66 | +1.05% |
| Aug 13, 2024 | $6.78 | $6.99 | +3.10% |
| May 08, 2024 | $5.18 | $5.16 | -0.39% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Zevra Therapeutics (ZVRA) report earnings?
Zevra Therapeutics (ZVRA) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Zevra Therapeutics (ZVRA) earnings time?
Zevra Therapeutics (ZVRA) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ZVRA EPS forecast?
ZVRA EPS forecast for the fiscal quarter 2025 (Q1) is -0.18.
---